Tirzepatide + Semaglutide
Pre-clinicalWithdrawn 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metabolic Health
Conditions
Metabolic Health
Trial Timeline
Jul 1, 2023 → Jul 1, 2023
NCT ID
NCT06354101About Tirzepatide + Semaglutide
Tirzepatide + Semaglutide is a pre-clinical stage product being developed by Eli Lilly for Metabolic Health. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06354101. Target conditions include Metabolic Health.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06354101 | Pre-clinical | Withdrawn |
| NCT05822830 | Phase 3 | Completed |
| NCT03987919 | Phase 3 | Completed |
Competing Products
20 competing products in Metabolic Health